The next generation of targeted biologic therapies for psoriasis will either be 
directed against new protein targets or improve on the efficacy, safety, or 
convenience of medications available for an already validated area in the immune 
response. Adalimumab is a fully human monoclonal antibody directed against tumor 
necrosis factor-alpha, a central cytokine in the immune response in psoriasis 
that has already been shown to be an effective target for therapy. This 
medication is approved by the US Food and Drug Administration (USFDA) for the 
treatment of rheumatoid arthritis. Early phrase II studies with adalimumab have 
shown excellent efficacy for psoriasis with either weekly or every other week 
subcutaneous injection. Moreover, the safety and tolerability of adalimumab in 
large clinical studies of rheumatoid arthritis have shown good results. Thus, 
adalimumab shows significant promise for the therapy of psoriasis in the future.